QuickView for TNRC13;jsessionid=3D765BD25ABDC6EF1EDE0A75B9F1BD6C;jsessionid=84A7B1B8F90E10C4BB8EF198E8862C87;jsessionid=086624F9ED561E2247AC960DF604F403;jsessionid=47BD8608FF341F1D3328BD9EEC561979;jsessionid=A043B438A3B5591667B8740B38982408;jsessionid=6522F86583777FE9575FA63A04BFDCC9;jsessionid=8F12C34BC9D825CC65D5EF4ABA58B4A8;jsessionid=F49A517B86BC90BE0F24042C7083C519;jsessionid=6F6EE2A1A22C97BE9B479318AD36CB8D;jsessionid=C219DED2038565B9EF13657783D2BF6E (gene)

1. Ataxin-2 sequesters Raptor into aggregates and impairs cellular mTORC1 signaling.
2. The polyglutamine protein ATXN2: from its molecular functions to its involvement in disease.
3. Clinical features, disease progression, and nuclear imaging in ATXN2-related parkinsonism in a longi…
4. ATXN2 is a target of N-terminal proteolysis.
5. A Case of Coexistent Spinocerebellar Ataxia Type 2 and Primary Progressive Multiple Sclerosis-Coinci…

There were no clinical trials for TNRC13;jsessionid=3D765BD25ABDC6EF1EDE0A75B9F1BD6C;jsessionid=84A7B1B8F90E10C4BB8EF198E8862C87;jsessionid=086624F9ED561E2247AC960DF604F403;jsessionid=47BD8608FF341F1D3328BD9EEC561979;jsessionid=A043B438A3B5591667B8740B38982408;jsessionid=6522F86583777FE9575FA63A04BFDCC9;jsessionid=8F12C34BC9D825CC65D5EF4ABA58B4A8;jsessionid=F49A517B86BC90BE0F24042C7083C519;jsessionid=6F6EE2A1A22C97BE9B479318AD36CB8D;jsessionid=C219DED2038565B9EF13657783D2BF6E